FENC
Fennec Pharmaceuticals Inc.
Price Chart
Latest Quote
$9.53
+0.47 (+5.19%)
Current Price
| Previous Close | $9.06 |
| Open | $9.44 |
| Day High | $9.53 |
| Day Low | $9.12 |
| Volume | 437,464 |
Stock Information
| Shares Outstanding | 34.74M |
| Cash Equivalents | $40.18M |
| Revenue | $51.00M |
| Net Income | $-8.38M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $331.04M |
| EPS (TTM) | $-0.29 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $290.86M |
| Sales | $51.00M |
| Income | $-8.38M |
| Book/sh | $1.09 |
| Cash/sh | $1.16 |
| Employees | 35 |
Financial Ratios
| Quick Ratio | 6.15 |
| Current Ratio | 6.98 |
Returns & Margins
| ROA | -5.91% |
| ROE | -52.68% |
| Gross Margin | 92.23% |
| Operating Margin | -0.79% |
| Profit Margin | -16.42% |
Ownership
| Insider Ownership | 14.42% |
| Institutional Ownership | 54.29% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 10.71 |
| PEG | 1.47 |
| P/S | 6.49 |
| P/B | 8.74 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $15.67 |
Technical Indicators
| SMA20 | $9.32 |
| SMA50 | $8.07 |
| SMA200 | $8.04 |
| RSI | 44.37 |
| ATR | 0.4837 |
| Shares Float | 14.22M |
| Short Float | 1.66% |
| Short Ratio | 1.40 |
| Volatility | 1.08 |
| Rel Volume | 1.49 |
Performance History
| Week | +5.89% |
| Month | -2.26% |
| Quarter | +30.19% |
| 6 Months | +26.39% |
| YTD | +24.09% |
| Year | +21.25% |
| 3 Years | +1.28% |
| 5 Years | +42.45% |
| 10 Years | -20.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $9.53 | 437,464 |
| 2026-06-18 | $9.06 | 372,700 |
| 2026-06-17 | $8.98 | 260,000 |
| 2026-06-16 | $8.96 | 248,600 |
| 2026-06-15 | $9.19 | 124,400 |
| 2026-06-12 | $9.00 | 251,300 |
| 2026-06-11 | $8.85 | 213,600 |
| 2026-06-10 | $8.70 | 144,200 |
| 2026-06-09 | $8.77 | 149,300 |
| 2026-06-08 | $8.90 | 321,400 |
| 2026-06-05 | $8.70 | 170,000 |
| 2026-06-04 | $9.16 | 183,900 |
| 2026-06-03 | $9.14 | 238,900 |
| 2026-06-02 | $9.98 | 352,600 |
| 2026-06-01 | $9.88 | 346,200 |
| 2026-05-29 | $9.93 | 447,800 |
| 2026-05-28 | $9.89 | 1,067,000 |
| 2026-05-27 | $9.97 | 219,600 |
| 2026-05-26 | $9.89 | 135,700 |
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
đ° Latest News
Insider Favorites High Growth Companies June 2026
Simply Wall St. âĸ 2026-06-08T11:35:56Z
Adherex Technologiesâ PEDMARK Push Targets Larger AYA Market After Record Quarter
MarketBeat âĸ 2026-05-23T14:05:45Z
Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting
MT Newswires âĸ 2026-05-22T11:21:54ZFennec Pharmaceuticals Inc (FENC) Q1 2026 Earnings Call Highlights: Record Sales Surge and ...
GuruFocus.com âĸ 2026-05-14T23:03:04ZFennec Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-14T21:11:37Z
Do Options Traders Know Something About Adherex Technologies Stock We Don't?
Zacks âĸ 2026-05-14T15:32:00Z
Adherex Technologies Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-14T15:06:58Z
Fennec Pharmaceuticals Shares Rise After Earnings and Revenue Beat Forecasts (FENC)
InvestorsHub âĸ 2026-05-14T12:47:47Z
Fennec Pharmaceuticals up 12.6% in U.S. Pre-Market on Q1 Earnings as Pedmark Sales Jump 73%
MT Newswires âĸ 2026-05-14T11:45:31ZAdherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-14T11:40:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,725,000 | $2,473,000 | $1,546,000 | $86,000 |
| Cost Of Revenue | $3,764,000 | $3,184,000 | $1,259,000 | $86,000 |
| Total Revenue | $44,642,000 | $47,538,000 | $21,252,000 | $1,535,000 |
| Operating Revenue | $44,642,000 | $47,538,000 | $21,252,000 | $1,535,000 |
| Expenses | ||||
| Interest Expense | $2,080,000 | $4,069,000 | $3,394,000 | $978,000 |
| Total Expenses | $50,988,000 | $45,059,000 | $34,310,000 | $24,273,000 |
| Other Income Expense | $-1,996,000 | $-163,000 | $-34,000 | $-193,000 |
| Net Non Operating Interest Income Expense | $-1,293,000 | $-2,387,000 | $-2,953,000 | $-783,000 |
| Interest Expense Non Operating | $2,080,000 | $4,069,000 | $3,394,000 | $978,000 |
| Operating Expense | $47,224,000 | $41,875,000 | $33,051,000 | $24,187,000 |
| Selling And Marketing Expense | $18,616,000 | $18,426,000 | $12,123,000 | $2,785,000 |
| General And Administrative Expense | $28,294,000 | $23,053,000 | $20,585,000 | $17,722,000 |
| Total Other Finance Cost | - | $89,000 | $287,000 | $149,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-9,741,000 | $-436,000 | $-16,045,000 | $-23,714,000 |
| Net Interest Income | $-1,293,000 | $-2,387,000 | $-2,953,000 | $-783,000 |
| Interest Income | $787,000 | $1,682,000 | $441,000 | $195,000 |
| Normalized Income | $-8,164,160 | $-307,230 | $-16,011,000 | $-23,521,000 |
| Net Income From Continuing And Discontinued Operation | $-9,741,000 | $-436,000 | $-16,045,000 | $-23,714,000 |
| Total Operating Income As Reported | $-6,282,000 | $2,568,000 | $-12,771,000 | $-22,589,000 |
| Net Income Common Stockholders | $-9,741,000 | $-436,000 | $-16,045,000 | $-23,714,000 |
| Net Income | $-9,741,000 | $-436,000 | $-16,045,000 | $-23,714,000 |
| Net Income Including Noncontrolling Interests | $-9,741,000 | $-436,000 | $-16,045,000 | $-23,714,000 |
| Net Income Continuous Operations | $-9,741,000 | $-436,000 | $-16,045,000 | $-23,714,000 |
| Pretax Income | $-9,635,000 | $-71,000 | $-16,045,000 | $-23,714,000 |
| Special Income Charges | $-2,022,000 | $0 | - | - |
| Interest Income Non Operating | $787,000 | $1,682,000 | $441,000 | $195,000 |
| Operating Income | $-6,346,000 | $2,479,000 | $-13,058,000 | $-22,738,000 |
| Depreciation Amortization Depletion Income Statement | $64,000 | $89,000 | $287,000 | $149,000 |
| Depreciation And Amortization In Income Statement | $64,000 | $89,000 | $287,000 | $149,000 |
| Amortization Of Intangibles Income Statement | $64,000 | $89,000 | $287,000 | $149,000 |
| Gross Profit | $40,878,000 | $44,354,000 | $19,993,000 | $1,449,000 |
| Per Share | ||||
| Diluted EPS | $-0.35 | $0.00 | $-0.60 | $-0.90 |
| Basic EPS | $-0.35 | $0.00 | $-0.60 | $-0.90 |
| Other | ||||
| Tax Effect Of Unusual Items | $-419,160 | $-34,230 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,456,000 | $4,961,000 | $-12,330,000 | $-22,394,000 |
| Total Unusual Items | $-1,996,000 | $-163,000 | $-34,000 | $-193,000 |
| Total Unusual Items Excluding Goodwill | $-1,996,000 | $-163,000 | $-34,000 | $-193,000 |
| Reconciled Depreciation | $103,000 | $800,000 | $0 | $149,000 |
| EBITDA (Bullshit earnings) | $-7,452,000 | $4,798,000 | $-12,364,000 | $-22,587,000 |
| EBIT | $-7,555,000 | $3,998,000 | $-12,651,000 | $-22,736,000 |
| Diluted Average Shares | $28,577,000 | $27,294,000 | $26,574,000 | $26,275,000 |
| Basic Average Shares | $28,577,000 | $27,294,000 | $26,574,000 | $26,275,000 |
| Diluted NI Availto Com Stockholders | $-9,741,000 | $-436,000 | $-16,045,000 | $-23,714,000 |
| Tax Provision | $106,000 | $365,000 | $0 | - |
| Other Special Charges | $2,022,000 | - | - | - |
| Gain On Sale Of Security | $26,000 | $-163,000 | $-34,000 | $-193,000 |
| Amortization | $64,000 | $89,000 | $287,000 | $149,000 |
| Research And Development | $250,000 | $307,000 | $56,000 | $3,531,000 |
| Selling General And Administration | $46,910,000 | $41,479,000 | $32,708,000 | $20,507,000 |
| Other Gand A | $28,294,000 | $23,053,000 | $20,585,000 | $17,722,000 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $35,472,000 | $-5,872,000 | $-11,622,000 | $-2,569,000 |
| Total Assets | $70,551,000 | $44,946,000 | $26,864,000 | $26,939,000 |
| Total Non Current Assets | $3,508,000 | $822,000 | $6,000 | $211,000 |
| Other Non Current Assets | $717,000 | $822,000 | $6,000 | - |
| Non Current Accounts Receivable | $2,791,000 | - | - | - |
| Current Assets | $67,043,000 | $44,124,000 | $26,858,000 | $26,728,000 |
| Other Current Assets | $1,731,000 | $466,000 | $44,000 | $63,000 |
| Prepaid Assets | $3,738,000 | $3,080,000 | $2,575,000 | $770,000 |
| Inventory | $1,565,000 | $1,060,000 | $2,156,000 | $576,000 |
| Receivables | $23,221,000 | $12,884,000 | $8,814,000 | $1,545,000 |
| Accounts Receivable | $23,221,000 | $12,884,000 | $8,814,000 | $1,545,000 |
| Allowance For Doubtful Accounts Receivable | $-2,103,000 | $-3,803,000 | - | - |
| Gross Accounts Receivable | $25,324,000 | $16,687,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $36,788,000 | $26,634,000 | $13,269,000 | $23,774,000 |
| Cash And Cash Equivalents | $36,788,000 | $26,634,000 | $13,269,000 | $23,774,000 |
| Non Current Deferred Assets | - | - | $6,000 | $211,000 |
| Debt | ||||
| Total Debt | $0 | $19,340,000 | $30,952,000 | $24,899,000 |
| Long Term Debt And Capital Lease Obligation | - | $19,338,000 | $30,931,000 | $24,899,000 |
| Long Term Debt | - | $19,338,000 | $30,931,000 | $24,899,000 |
| Current Debt And Capital Lease Obligation | - | $2,000 | $21,000 | - |
| Net Debt | - | - | $17,662,000 | $1,125,000 |
| Liabilities | ||||
| Total Non Current Liabilities Net Minority Interest | $24,561,000 | $43,899,000 | $30,933,000 | $24,899,000 |
| Non Current Deferred Liabilities | $24,561,000 | $24,561,000 | $2,000 | - |
| Current Liabilities | $10,518,000 | $6,919,000 | $7,553,000 | $4,609,000 |
| Current Deferred Liabilities | $248,000 | $248,000 | $0 | - |
| Payables And Accrued Expenses | $10,270,000 | $6,669,000 | $7,532,000 | $4,609,000 |
| Payables | $4,635,000 | $3,241,000 | $3,778,000 | $2,390,000 |
| Accounts Payable | $4,635,000 | $3,241,000 | $3,778,000 | $2,390,000 |
| Equity | ||||
| Common Stock Equity | $35,472,000 | $-5,872,000 | $-11,622,000 | $-2,569,000 |
| Total Equity Gross Minority Interest | $35,472,000 | $-5,872,000 | $-11,622,000 | $-2,569,000 |
| Stockholders Equity | $35,472,000 | $-5,872,000 | $-11,622,000 | $-2,569,000 |
| Gains Losses Not Affecting Retained Earnings | $1,243,000 | $1,243,000 | $1,243,000 | $1,243,000 |
| Other Equity Adjustments | $1,243,000 | $1,243,000 | $1,243,000 | $1,243,000 |
| Retained Earnings | $-229,422,000 | $-219,681,000 | $-219,245,000 | $-203,200,000 |
| Other | ||||
| Ordinary Shares Number | $34,163,000 | $27,527,000 | $27,027,000 | $26,361,000 |
| Share Issued | $34,163,000 | $27,527,000 | $27,027,000 | $26,361,000 |
| Tangible Book Value | $35,472,000 | $-5,872,000 | $-11,622,000 | $-2,569,000 |
| Invested Capital | $35,472,000 | $13,466,000 | $19,309,000 | $22,330,000 |
| Working Capital | $56,525,000 | $37,205,000 | $19,305,000 | $22,119,000 |
| Capital Lease Obligations | $0 | $2,000 | $21,000 | $0 |
| Total Capitalization | $35,472,000 | $13,466,000 | $19,309,000 | $22,330,000 |
| Additional Paid In Capital | $73,745,000 | $66,958,000 | $62,073,000 | $56,797,000 |
| Capital Stock | $189,906,000 | $145,608,000 | $144,307,000 | $142,591,000 |
| Common Stock | $189,906,000 | $145,608,000 | $144,307,000 | $142,591,000 |
| Non Current Deferred Revenue | $24,561,000 | $24,561,000 | $2,000 | - |
| Current Deferred Revenue | $248,000 | $248,000 | $0 | - |
| Current Capital Lease Obligation | $0 | $2,000 | $21,000 | $0 |
| Current Accrued Expenses | $5,635,000 | $3,428,000 | $3,754,000 | $2,219,000 |
| Treasury Shares Number | - | - | $0 | - |
| Long Term Capital Lease Obligation | - | - | $2,000 | $0 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,473,000 | $26,980,000 | $-17,143,000 | $-18,058,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,473,000 | $26,980,000 | $-17,143,000 | $-18,058,000 |
| Cash Flow From Continuing Operating Activities | $-12,473,000 | $26,980,000 | $-17,143,000 | $-18,058,000 |
| Operating Gains Losses | $2,022,000 | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $42,049,000 | $0 | - | - |
| Financing Cash Flow | $22,627,000 | $-13,615,000 | $6,638,000 | $20,732,000 |
| Cash Flow From Continuing Financing Activities | $22,627,000 | $-13,615,000 | $6,638,000 | $20,732,000 |
| Net Other Financing Charges | $-2,135,000 | $-1,916,000 | $-75,000 | $-131,000 |
| Net Common Stock Issuance | $42,049,000 | $0 | - | - |
| Common Stock Issuance | $42,049,000 | $0 | - | - |
| Other | ||||
| Repayment Of Debt | $-19,477,000 | $-13,000,000 | $0 | $-5,000,000 |
| Interest Paid Supplemental Data | $4,160,000 | $3,821,000 | - | - |
| Income Tax Paid Supplemental Data | $748,000 | $0 | - | - |
| End Cash Position | $36,788,000 | $26,634,000 | $13,269,000 | $23,774,000 |
| Beginning Cash Position | $26,634,000 | $13,269,000 | $23,774,000 | $21,100,000 |
| Changes In Cash | $10,154,000 | $13,365,000 | $-10,505,000 | $2,674,000 |
| Proceeds From Stock Option Exercised | $2,190,000 | $1,301,000 | $1,716,000 | $928,000 |
| Net Issuance Payments Of Debt | $-19,477,000 | $-13,000,000 | $4,997,000 | $19,935,000 |
| Net Long Term Debt Issuance | $-19,477,000 | $-13,000,000 | $4,997,000 | $19,935,000 |
| Long Term Debt Payments | $-19,477,000 | $-13,000,000 | $0 | $-5,000,000 |
| Change In Working Capital | $-12,042,000 | $16,943,000 | $-6,778,000 | $1,103,000 |
| Change In Other Current Assets | $-1,267,000 | $796,000 | $3,000 | $6,000 |
| Change In Payables And Accrued Expense | $3,601,000 | $-863,000 | $1,964,000 | $2,954,000 |
| Change In Accrued Expense | $2,207,000 | $-326,000 | $576,000 | $1,342,000 |
| Change In Payable | $1,394,000 | $-537,000 | $1,388,000 | $1,612,000 |
| Change In Account Payable | $1,394,000 | $-537,000 | $1,388,000 | $1,612,000 |
| Change In Prepaid Assets | $-658,000 | $-505,000 | $104,000 | $264,000 |
| Change In Inventory | $-1,278,000 | $579,000 | $-1,580,000 | $-576,000 |
| Change In Receivables | $-12,440,000 | $-7,873,000 | $-7,269,000 | $-1,545,000 |
| Changes In Account Receivables | $-12,440,000 | $-7,873,000 | $-7,269,000 | $-1,545,000 |
| Other Non Cash Items | $-2,726,000 | $211,000 | $287,000 | $282,000 |
| Stock Based Compensation | $7,033,000 | $5,061,000 | $5,354,000 | $4,087,000 |
| Unrealized Gain Loss On Investment Securities | $2,000 | $81,000 | $39,000 | $184,000 |
| Provisionand Write Offof Assets | $2,876,000 | $4,320,000 | $0 | - |
| Depreciation Amortization Depletion | $103,000 | $800,000 | $0 | - |
| Depreciation And Amortization | $103,000 | $800,000 | $0 | - |
| Amortization Cash Flow | $103,000 | $800,000 | $0 | - |
| Amortization Of Intangibles | $103,000 | $800,000 | $0 | - |
| Net Income From Continuing Operations | $-9,741,000 | $-436,000 | $-16,045,000 | $-23,714,000 |
| Change In Other Working Capital | - | $24,809,000 | - | - |
| Issuance Of Debt | - | - | $4,997,000 | $24,935,000 |
| Long Term Debt Issuance | - | - | $4,997,000 | $24,935,000 |
Fetched: 2026-06-21